



David Anstice Elected to Alkermes' Board of Directors

October 8, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced the election of David Anstice to the company's Board of Directors. Mr. Anstice brings more than 30 years of experience serving in executive management positions and leading major global activities in the pharmaceutical industry.

"We are very pleased to welcome David to our Board, as he has long-standing experience as a senior pharmaceutical executive with a unique perspective on growing biotech businesses," said Richard F. Pops, Chairman of the Board of Directors of Alkermes. "We look forward to his contributions as we work toward enhancing the company's business and accelerating its growth."

During his career, Mr. Anstice served as Executive Vice President of Merck & Co. and also as its President of Global Human Health. Previously, Mr. Anstice was President, Asia Pacific Human Health, for Merck where he was responsible for the company's Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions with its worldwide ventures, including President, U.S. Human Health. At Alkermes, Mr. Anstice will be an independent director and will serve on the Board's Compensation Committee.

"Alkermes' strong financial profile, driven by growing sales of RISPERDAL(R) CONSTA(R), coupled with the potential of exenatide once weekly and innovative pipeline, represents a unique opportunity in the industry," commented Mr. Anstice. "The company is well-positioned to become a significant biopharmaceutical commercial enterprise. I very much look forward to working with the talented Board and management team of Alkermes."

About Alkermes

Alkermes, Inc., a biotechnology company committed to developing innovative medicines to improve patients' lives, manufactures RISPERDAL(R) CONSTA(R) for schizophrenia and developed and manufactures VIVITROL(R) for alcohol dependence. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research and manufacturing facilities in Massachusetts and Ohio.

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. For information with respect to risks and uncertainties that could cause the company's actual results to differ materially from expectations, reference is made to the reports the company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and the company disclaims any intention or responsibility for updating predictions or financial expectations contained in this release.

Source: Alkermes, Inc.